Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: Mechanisms, human evidence, therapeutic implications, and preventive implications

Seminars in Liver Disease

Volumn 32, Issue 1, 2012, Pages 39-48

  Northup, Patrick G ^a   Argo, Curtis K ^a   Shah, Neeral ^a   Caldwell, Stephen H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

coagulopathy; hepatitis; steatohepatitis; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K;

ACUTE HEART INFARCTION; CEREBROVASCULAR ACCIDENT; EPIDEMIOLOGICAL DATA; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; MEDICAL LITERATURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; POPULATION BASED CASE CONTROL STUDY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; THROMBOPHILIA; UNSTABLE ANGINA PECTORIS;

ANTICOAGULANTS; FATTY LIVER; HEPATITIS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOPHILIA;

EID: 84857955363     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0032-1306425     Document Type: Review

References (121)

1. Ekstedt M, Franzn LE, Mathiesen UL., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology: 2006; 44 4 865 873 (Pubitemid 46489550)
2. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis: 2008; 28 4 339 350
3. Williams CD, Stengel J, Asike MI., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology: 2011; 140 1 124 131
4. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology: 2007; 132 6 2169 2180 (Pubitemid 46693756)
5. Adams LA, Harmsen S, St Sauver JL., et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol: 2010; 105 7 1567 1573
6. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA: 2010; 303 3 235 241
7. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology: 2011; 141 4 1249 1253
8. Targher G, Bertolini L, Rodella S., et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring): 2008; 16 6 1394 1399 (Pubitemid 351770539)
9. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med: 2000; 343 20 1467 1476
10. Targher G, Zoppini G, Moghetti P, Day CP. Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin Thromb Hemost: 2010; 36 1 41 48
11. Thuy S, Ladurner R, Volynets V., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr: 2008; 138 8 1452 1455
12. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost: 2009; 35 3 277 287
13. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol: 1996; 16 3 368 374 (Pubitemid 26084311)
14. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy menrole of the metabolic syndrome. Thromb Haemost: 1996; 76 1 69 73 (Pubitemid 26254319)
15. Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol: 2007; 46 6 1126 1132 (Pubitemid 46669732)
16. Targher G, Bertolini L, Padovani R., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care: 2007; 30 5 1212 1218 (Pubitemid 46684650)
17. Targher G, Bertolini L, Rodella S., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care: 2007; 30 8 2119 2121 (Pubitemid 47219432)
18. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med: 2010; 363 14 1341 1350
19. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis: 2009; 13 4 511 531
20. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology: 2008; 134 2 424 431 (Pubitemid 351173050)
21. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology: 2002; 35 4 898 904 (Pubitemid 34258385)
22. Fujita K, Nozaki Y, Wada K., et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology: 2009; 50 3 772 780
23. Musso G, Gambino R, De Michieli F., et al. Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. Ann Med: 2008; 40 5 383 394 (Pubitemid 351882891)
24. Ohsaki Y, Cheng J, Suzuki M, Fujita A, Fujimoto T. Lipid droplets are arrested in the ER membrane by tight binding of lipidated apolipoprotein B-100. J Cell Sci: 2008; 121 Pt 14 2415 2422
25. Caldwell S, Ikura Y, Dias D., et al. Hepatocellular ballooning in NASH. J Hepatol: 2010; 53 4 719 723
26. Ikura Y, Ohsawa M, Suekane T., et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology: 2006; 43 3 506 514
27. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol: 2008; 48 5 821 828
28. Itabe H, Takeshima E, Iwasaki H., et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem: 1994; 269 21 15274 15279
29. Garca-Monzn C, Martn-Prez E, Iacono OL., et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol: 2000; 33 5 716 724
30. Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol: 2005; 42 4 585 591 (Pubitemid 40342940)
31. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol: 2002; 37 1 56 62 (Pubitemid 34713055)
32. Albano E, Mottaran E, Vidali M., et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut: 2005; 54 7 987 993 (Pubitemid 40873914)
33. Puri P, Wiest MM, Cheung O., et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology: 2009; 50 6 1827 1838
34. Alessi MC, Bastelica D, Mavri A., et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol: 2003; 23 7 1262 1268 (Pubitemid 36873814)
35. Allison BA, Nilsson L, Karpe F, Hamsten A, Eriksson P. Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arterioscler Thromb Vasc Biol: 1999; 19 5 1354 1360 (Pubitemid 29227658)
36. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol: 2003; 14 5 421 430 (Pubitemid 37297296)
37. Bochkov VN, Mechtcheriakova D, Lucerna M., et al. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood: 2002; 99 1 199 206
38. Sommeijer DW, Hansen HR, van Oerle R., et al. Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with Type 2 diabetes. J Thromb Haemost: 2006; 4 3 574 580
39. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology: 2008; 47 5 1495 1503 (Pubitemid 351702733)
40. Singh R, Kaushik S, Wang Y., et al. Autophagy regulates lipid metabolism. Nature: 2009; 458 7242 1131 1135
41. Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology: 2005; 129 1 351 360 (Pubitemid 41002067)
42. Owens AP III, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res: 2011; 108 10 1284 1297
43. Baron M, Leroyer AS, Majd Z., et al. PPAR activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. Atherosclerosis: 2011; 18 1 69 76
44. Leroyer AS, Isobe H, Lesche G., et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol: 2007; 49 7 772 777 (Pubitemid 46240708)
45. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care: 2004; 27 10 2498 2500 (Pubitemid 39281410)
46. Targher G, Bertolini L, Padovani R., et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care: 2006; 29 6 1325 1330 (Pubitemid 44125930)
47. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol: 2008; 49 4 600 607
48. Villanova N, Moscatiello S, Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology: 2005; 42 2 473 480 (Pubitemid 41061101)
49. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol: 2008; 28 1 27 38
50. Targher G, Bertolini L, Poli F., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes: 2005; 54 12 3541 3546 (Pubitemid 43334347)
51. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab: 2008; 93 11, Suppl 1 S74 S80
52. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol: 2005; 11 31 4838 4842
53. Mirbagheri SA, Rashidi A, Abdi S, Saedi D, Abouzari M. Liver: an alarm for the heart? Liver Int: 2007; 27 7 891 894
54. Hamaguchi M, Kojima T, Takeda N., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol: 2007; 13 10 1579 1584 (Pubitemid 46672668)
55. Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology: 2009; 50 5 1403 1411
56. Söderberg C, Stl P, Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology: 2010; 51 2 595 602
57. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol: 2008; 49 4 608 612
58. Rafiq N, Bai C, Fang Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol: 2009; 7 2 234 238
59. Northup PG, McMahon MM, Ruhl AP., et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol: 2006; 101 7 1524 1528, quiz 1680 (Pubitemid 43980626)
60. Forssen U, Kobayashi M, Moylan CA, Ludema CM, Theodore D. Nash increases the risk of portal vein thrombosis in patients on the liver transplant waiting list. Hepatology: 2010; 52 4 911a 911a, abstract
61. Northup PG, Sundaram V, Fallon MB., et al. Coagulation in Liver Disease Group. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost: 2008; 6 1 2 9
62. Laryea M, Watt KD, Molinari M., et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl: 2007; 13 8 1109 1114 (Pubitemid 47305029)
63. Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant: 2009; 9 4 782 793
64. Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl: 2009; 15 12 1814 1820
65. Dirckx JH, Armand J. Quick: pioneer and prophet of coagulation research. Ann Intern Med: 1980; 92 4 553 558
66. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther: 2007; 26 2 141 148 (Pubitemid 46985499)
67. Lisman T, van Leeuwen Y, Adelmeijer J., et al. Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int: 2008; 28 10 1344 1351
68. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant: 2007; 7 6 1624 1628 (Pubitemid 46776260)
69. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med: 2011; 365 2 147 156
70. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol: 2004; 99 6 1160 1174 (Pubitemid 38917824)
71. Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Assessment of fibrosis and cirrhosis in liver biopsies: an update. Semin Liver Dis: 2011; 31 1 82 90
72. Ratziu V, Charlotte F, Heurtier A., et al. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology: 2005; 128 7 1898 1906 (Pubitemid 40824701)
73. Tripodi A, Primignani M, Chantarangkul V., et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology: 2006; 44 2 440 445 (Pubitemid 44214883)
74. Tripodi A, Salerno F, Chantarangkul V., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology: 2005; 41 3 553 558 (Pubitemid 40289502)
75. Dahlbäck B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol: 2004; 79 2 109 116 (Pubitemid 38281808)
76. Tripodi A, Primignani M, Chantarangkul V., et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology: 2009; 137 6 2105 2111
77. Lisman T, Adelmeijer J, de Groot PG, Janssen HL, Leebeek FW. No evidence for an intrinsic platelet defect in patients with liver cirrhosisstudies under flow conditions. J Thromb Haemost: 2006; 4 9 2070 2072 (Pubitemid 44226796)
78. Lisman T, Bongers TN, Adelmeijer J., et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology: 2006; 44 1 53 61 (Pubitemid 44049138)
79. Basili S, Ferro D, Leo R., et al. Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis. The CALC Group. Coagulation abnormalities in liver cirrhosis. J Hepatol: 1996; 24 5 574 580 (Pubitemid 26167583)
80. Despotis GJ, Levine V, Filos KS., et al. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology: 1996; 85 6 1311 1323 (Pubitemid 27014658)
81. Mallett SV, Cox DJ. Thrombelastography. Br J Anaesth: 1992; 69 3 307 313
82. Spiess BD. Thromboelastography and cardiopulmonary bypass. Semin Thromb Hemost: 1995; 21 Suppl 4 27 33 (Pubitemid 26015178)
83. Viola F, Mauldin FW Jr, Lin-Schmidt X, Haverstick DM, Lawrence MB, Walker WF. A novel ultrasound-based method to evaluate hemostatic function of whole blood. Clin Chim Acta: 2010; 411 1-2 106 113
84. Amitrano L, Guardascione MA, Ames PR. Coagulation abnormalities in cirrhotic patients with portal vein thrombosis. Clin Lab: 2007; 53 9-12 583 589 (Pubitemid 351166424)
85. Sgaard KK, Horvth-Puh E, Grnbaek H, Jepsen P, Vilstrup H, Srensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol: 2009; 104 1 96 101
86. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther: 2010; 31 3 366 374
87. Qi X, Han G, Wu K, Fan D. Anticoagulation for portal vein thrombosis in cirrhosis. Am J Med: 2010; 123 9 e19 e20, author reply e21
88. Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med: 2002; 346 19 1468 1474 (Pubitemid 34755716)
89. Mohr JP, Thompson JL, Lazar RM., et al. Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med: 2001; 345 20 1444 1451
90. Menguy R, Desbaillets L, Okabe S, Masters YF. Abnormal aspirin metabolism in patients with cirrhosis and its possible relationship to bleeding in cirrhotics. Ann Surg: 1972; 176 3 412 418
91. Rainsford KD, Ford NL, Brooks PM, Watson HM. Plasma aspirin esterases in normal individuals, patients with alcoholic liver disease and rheumatoid arthritis: characterization and the importance of the enzymic components. Eur J Clin Invest: 1980; 10 5 413 420 (Pubitemid 11225574)
92. Kalaitzakis E, Rosengren A, Skommevik T, Björnsson E. Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci: 2010; 55 2 467 475
93. Song JY, Choi JY, Ko JT., et al. Long-term aspirin therapy for hepatopulmonary syndrome. Pediatrics: 1996; 97 6 Pt 1 917 920 (Pubitemid 26170959)
94. Ridker PM, Cook NR, Lee IM., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med: 2005; 352 13 1293 1304
95. Wright M, Goldin R, Hellier S., et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut: 2003; 52 8 1206 1210 (Pubitemid 36877437)
96. Bechmann LP, Sichau M, Wichert M, Gerken G, Kröger K, Hilgard P. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int: 2011; 31 1 75 82
97. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology: 2011; 54 5 1631 1639
98. Sanyal AJ, Chalasani N, Kowdley KV., et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med: 2010; 362 18 1675 1685
99. Adams LA, Angulo P, Petz J, Keach J, Lindor KD. A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int: 2010; 4 3 628 633
100. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol: 2009; 2 3 157 163
101. Chalasani NP, Sanyal AJ, Kowdley KV., et al. NASH CRN Research Group. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials: 2009; 30 1 88 96
102. Targher G. Pioglitazone in nonalcoholic steatohepatitis. N Engl J Med: 2007; 356 10 1067, author reply 1068-1069
103. Belfort R, Harrison SA, Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med: 2006; 355 22 2297 2307 (Pubitemid 44837778)
104. Sanyal AJ, Mofrad PS, Contos MJ., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol: 2004; 2 12 1107 1115 (Pubitemid 40037642)
105. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol: 2003; 98 11 2485 2490 (Pubitemid 37448761)
106. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology: 1995; 21 5 1238 1247
107. Goodman ZD, Stoddard AM, Bonkovsky HL., et al. HALT-C Trial Group. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology: 2009; 50 6 1738 1749
108. McHutchison J, Goodman Z, Patel K., et al. Farglitizar Study Investigators. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology: 2010; 138 4 1365 1373, 1373, e1-e2
109. Muir AJ, Sylvestre PB, Rockey DC. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat: 2006; 13 5 322 328
110. Anstee QM, Dhar A, Thursz MR. The role of hypercoagulability in liver fibrogenesis. Clin Res Hepatol Gastroenterol: 2011; 35 8-9 526 533
111. Anstee QM, Goldin RD, Wright M, Martinelli A, Cox R, Thursz MR. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost: 2008; 6 8 1336 1343 (Pubitemid 352016314)
112. Duplantier JG, Dubuisson L, Senant N., et al. A role for thrombin in liver fibrosis. Gut: 2004; 53 11 1682 1687 (Pubitemid 39434115)
113. Ibrahim M, Farghaly E, Gomaa W, Kelleni M, Abdelrahman AM. Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. Eur J Pharmacol: 2011; 659 2-3 289 295
114. Assy N, Hussein O, Khalil A., et al. The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci: 2007; 52 5 1187 1193 (Pubitemid 46626191)
115. Papatheodoridis GV, Papakonstantinou E, Andrioti E., et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut: 2003; 52 3 404 409 (Pubitemid 36250062)
116. Poujol-Robert A, Bolle PY, Poupon R, Robert A. Factor V. Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. Hepatology: 2004; 39 4 1174 1175 (Pubitemid 38428958)
117. Goulding C, O'Brien C, Egan H., et al. The impact of inherited prothrombotic risk factors on individuals chronically infected with hepatitis C virus from a single source. J Viral Hepat: 2007; 14 4 255 259 (Pubitemid 46452412)
118. Shi J, Hao JH, Ren WH, Zhu JR. Effects of heparin on liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol: 2003; 9 7 1611 1614 (Pubitemid 36992367)
119. Papatheodoridis GV, Chrysanthos N, Cholongitas E., et al. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J Hepatol: 2009; 51 5 931 938
120. Dhar A, Anstee QM, Cobbold JF., et al. Anticoagulation for liver fibrosis: a pilot study in hepatitis C infected patients. Hepatology: 2010; 52 4 1133a 1133a
121. Northup PG, Caldwell SH. New concepts of coagulation and bleeding in liver disease. Intern Emerg Med: 2010; 5 1 3 6